Skip to Main Content

Cancer vaccines are experiencing a bit of a resurgence, as we see in the new $70 million fundraise from Neon Therapeutics.

The startup, based in Cambridge, Mass., is developing cancer vaccines that target neoantigens — that is, substances that are unique to the surface of cancer cells.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!